A detailed history of Prelude Capital Management, LLC transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 16,508 shares of AQST stock, worth $75,771. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,508
Previous 16,508 -0.0%
Holding current value
$75,771
Previous $82,000 -0.0%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.4 - $5.09 $172,516 - $365,879
-71,882 Reduced 81.32%
16,508 $82,000
Q2 2024

Aug 14, 2024

BUY
$2.31 - $4.5 $146,902 - $286,173
63,594 Added 256.47%
88,390 $229,000
Q1 2024

May 15, 2024

BUY
$2.01 - $6.09 $49,839 - $151,007
24,796 New
24,796 $105,000
Q1 2019

May 15, 2019

SELL
$5.74 - $8.05 $1,153 - $1,618
-201 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$6.09 - $18.0 $1,224 - $3,618
201 New
201 $1,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $245M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.